-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Recommendation of "Hold" From Brokerages
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Recommendation of "Hold" From Brokerages
Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) have been assigned an average recommendation of "Hold" from the thirteen brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $101.70.
A number of equities research analysts have commented on the company. Cowen lowered their target price on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Piper Sandler lowered their target price on Tandem Diabetes Care from $120.00 to $80.00 and set an "overweight" rating on the stock in a report on Thursday, August 4th. StockNews.com cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a report on Friday. Lake Street Capital reduced their price target on Tandem Diabetes Care from $200.00 to $150.00 in a research note on Thursday, August 4th. Finally, Cowen reduced their price target on Tandem Diabetes Care from $141.00 to $107.00 in a research note on Thursday, August 4th.
Get Tandem Diabetes Care alerts:Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in TNDM. Fifth Third Bancorp raised its position in shares of Tandem Diabetes Care by 358.3% in the 2nd quarter. Fifth Third Bancorp now owns 440 shares of the medical device company's stock worth $26,000 after buying an additional 344 shares during the period. Quadrant Capital Group LLC raised its position in shares of Tandem Diabetes Care by 244.7% in the 2nd quarter. Quadrant Capital Group LLC now owns 517 shares of the medical device company's stock worth $31,000 after buying an additional 367 shares during the period. Exane Derivatives purchased a new position in shares of Tandem Diabetes Care in the 1st quarter worth $33,000. Byrne Asset Management LLC purchased a new position in Tandem Diabetes Care in the fourth quarter valued at about $34,000. Finally, CI Investments Inc. raised its position in Tandem Diabetes Care by 10,566.7% in the first quarter. CI Investments Inc. now owns 320 shares of the medical device company's stock valued at $37,000 after purchasing an additional 317 shares during the period. 95.28% of the stock is owned by hedge funds and other institutional investors.
Tandem Diabetes Care Stock Performance
Shares of NASDAQ:TNDM opened at $55.98 on Friday. The business's fifty day moving average price is $55.47 and its two-hundred day moving average price is $78.24. The company has a current ratio of 6.00, a quick ratio of 5.36 and a debt-to-equity ratio of 0.63. Tandem Diabetes Care has a one year low of $42.90 and a one year high of $155.86.About Tandem Diabetes Care
(Get Rating)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Read More
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) have been assigned an average recommendation of "Hold" from the thirteen brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $101.70.
据Marketbeat报道,目前涵盖Tandem糖尿病护理公司(纳斯达克代码:TNDM-GET)的13家券商给出了该公司股票的平均建议为持有。两名分析师对该股的评级为卖出建议,两名分析师给出了持有建议,两名分析师给出了买入建议。去年更新了对该股覆盖范围的经纪商的平均12个月目标价为101.70美元。
A number of equities research analysts have commented on the company. Cowen lowered their target price on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Piper Sandler lowered their target price on Tandem Diabetes Care from $120.00 to $80.00 and set an "overweight" rating on the stock in a report on Thursday, August 4th. StockNews.com cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a report on Friday. Lake Street Capital reduced their price target on Tandem Diabetes Care from $200.00 to $150.00 in a research note on Thursday, August 4th. Finally, Cowen reduced their price target on Tandem Diabetes Care from $141.00 to $107.00 in a research note on Thursday, August 4th.
许多股票研究分析师对该公司发表了评论。Cowen在8月4日星期四的一份报告中将Tandem糖尿病护理的目标价格从141.00美元下调至107.00美元。派珀·桑德勒在8月4日周四的一份报告中将Tandem糖尿病护理公司的目标价从120.00美元下调至80美元,并对该股设定了“增持”评级。在周五的一份报告中,StockNews.com将Tandem糖尿病护理公司的评级从“持有”下调至“卖出”。Lake Street Capital在8月4日星期四的一份研究报告中将他们的Tandem糖尿病护理目标价从200.00美元下调至150.00美元。最后,考恩在8月4日星期四的一份研究报告中将Tandem糖尿病护理的目标价格从141.00美元下调至107.00美元。
Institutional Inflows and Outflows
机构资金流入和流出
Several large investors have recently made changes to their positions in TNDM. Fifth Third Bancorp raised its position in shares of Tandem Diabetes Care by 358.3% in the 2nd quarter. Fifth Third Bancorp now owns 440 shares of the medical device company's stock worth $26,000 after buying an additional 344 shares during the period. Quadrant Capital Group LLC raised its position in shares of Tandem Diabetes Care by 244.7% in the 2nd quarter. Quadrant Capital Group LLC now owns 517 shares of the medical device company's stock worth $31,000 after buying an additional 367 shares during the period. Exane Derivatives purchased a new position in shares of Tandem Diabetes Care in the 1st quarter worth $33,000. Byrne Asset Management LLC purchased a new position in Tandem Diabetes Care in the fourth quarter valued at about $34,000. Finally, CI Investments Inc. raised its position in Tandem Diabetes Care by 10,566.7% in the first quarter. CI Investments Inc. now owns 320 shares of the medical device company's stock valued at $37,000 after purchasing an additional 317 shares during the period. 95.28% of the stock is owned by hedge funds and other institutional investors.
几个大型投资者最近改变了他们在TNDM的头寸。Five Third Bancorp在第二季度将其在Tandem糖尿病护理公司的股票头寸提高了358.3%。Five Third Bancorp在此期间又购买了344股,现在拥有440股这家医疗设备公司的股票,价值2.6万美元。跨骏资本集团在第二季度将其在Tandem糖尿病护理公司的股票头寸增加了244.7%。跨骏资本集团现在持有这家医疗设备公司517股股票,价值3.1万美元,在此期间又购买了367股。Exane衍生品公司在第一季度购买了Tandem糖尿病护理公司的新股票,价值3.3万美元。Byrne Asset Management LLC在第四季度收购了Tandem糖尿病护理公司的一个新头寸,价值约3.4万美元。最后,CI投资公司在第一季度将其在Tandem糖尿病护理领域的地位提高了10566.7%。CI Investments Inc.在此期间又购买了317股,现在拥有320股这家医疗设备公司的股票,价值3.7万美元。95.28%的股票由对冲基金和其他机构投资者持有。
Tandem Diabetes Care Stock Performance
串联糖尿病护理股票表现
About Tandem Diabetes Care
关于糖尿病患者的护理
(Get Rating)
(获取评级)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Tandem糖尿病护理公司是一家医疗设备公司,为美国和国际上的胰岛素依赖型糖尿病患者设计、开发和销售各种产品。该公司的旗舰产品是T:SILM X2胰岛素输送系统,这是一个由T:SILM X2泵、300个单位的一次性胰岛素盒和输液器组成的泵平台。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于串联糖尿病护理(TNDM)的研究报告
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏,这些股票可能表现优异
- DocuSign是否即将发生重大逆转?
- 石油和天然气股票:投资可再生能源的安全途径
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
接受每日串联糖尿病护理的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Tandem糖尿病护理和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧